4.20

7.28% -0.33

After Hours: 4.20

Karyopharm Therapeutics Inc (KPTI)

Overview News Price History Option Chain Financials Discussions Forecast

Karyopharm Therapeutics Inc stock is traded at $4.20, with a volume of 109.89K. It is down -7.28% in the last 24 hours and down -37.78% over the past month. Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

Previous Close:

$4.53

Open:

$4.48

24h Volume:

109.89K

Relative Volume:

0.89

Market Cap:

$36.29M

Revenue:

$140.46M

Net Income/Loss:

$-146.34M

P/E Ratio:

-3.3071

EPS:

-1.27

Net Cash Flow:

$-117.73M

1W Performance:

-8.50%

1M Performance:

-37.78%

6M Performance:

-66.87%

1Y Performance:

-70.47%

1-Day Range:

$4.15

$4.6468

1-Week Range:

$4.15

$4.8132

52-Week Range:

$3.51

$17.40

Karyopharm Therapeutics Inc Stock (KPTI) Company Profile

Name

Karyopharm Therapeutics Inc

Sector

Healthcare (1177)

Industry

Biotechnology (671)

Phone

617-658-0600

Address

85 WELLS AVENUE, NEWTON, MA

Employee

279

Twitter

@Karyopharm

Next Earnings Date

2024-11-05

Latest SEC Filings

KPTI's Discussions on Twitter

Compare KPTI with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KPTI Karyopharm Therapeutics Inc	4.20	40.09M	140.46M	-146.34M	-117.73M	-1.27
ONC Beone Medicines Ltd Adr	245.58	25.81B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	441.85	111.46B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.35	40.37M	0	0	0	0.00
VRNA Verona Pharma Plc Adr	81.16	6.19B	0	-153.72M	-103.81M	-2.00
REGN Regeneron Pharmaceuticals Inc	489.52	64.44B	14.09B	4.50B	2.96B	39.28

Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-19-23	Initiated	Piper Sandler	Overweight
Nov-04-22	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Feb-09-22	Upgrade	JP Morgan	Underweight → Neutral
Nov-19-21	Resumed	Morgan Stanley	Equal-Weight
Aug-06-21	Downgrade	JP Morgan	Overweight → Neutral
Aug-06-21	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Aug-06-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jul-02-20	Initiated	Morgan Stanley	Overweight
Mar-04-20	Initiated	Barclays	Overweight
Jan-17-20	Downgrade	Wedbush	Outperform → Neutral
Jul-23-19	Upgrade	JP Morgan	Neutral → Overweight
Jul-05-19	Reiterated	H.C. Wainwright	Buy
Jul-05-19	Reiterated	Robert W. Baird	Outperform
Mar-01-19	Downgrade	JP Morgan	Overweight → Neutral
Feb-28-19	Reiterated	BofA/Merrill	Underperform
Feb-27-19	Downgrade	BofA/Merrill	Neutral → Underperform
Jan-03-19	Upgrade	BofA/Merrill	Underperform → Neutral
Dec-03-18	Initiated	B. Riley FBR	Buy
Nov-09-18	Upgrade	Wedbush	Neutral → Outperform
May-24-18	Downgrade	Wedbush	Outperform → Neutral
Apr-02-18	Resumed	Leerink Partners	Outperform
Nov-15-17	Resumed	H.C. Wainwright	Buy
Sep-15-17	Initiated	RBC Capital Mkts	Outperform
Sep-08-16	Reiterated	H.C. Wainwright	Buy
Aug-30-16	Upgrade	Jefferies	Hold → Buy
Aug-18-16	Initiated	H.C. Wainwright	Buy
Jun-28-16	Initiated	Robert W. Baird	Outperform

View All

Karyopharm Therapeutics Inc Stock (KPTI) Latest News

03:25 AM

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Shares Acquired by Jane Street Group LLC - Defense World

03:25 AM

May 29, 2025

Karyopharm increases share reserve for equity plan By Investing.com - Investing.com India

May 29, 2025

Karyopharm Therapeutics Stockholders Approve Equity Plan Amendment - TipRanks

May 29, 2025

Karyopharm increases share reserve for equity plan - Investing.com

May 29, 2025

D. E. Shaw & Co. Inc. Sells 817,711 Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - Defense World

May 29, 2025

May 28, 2025

Hepatic Impairment Market Predicted to See Upsurge Through 2032, Highlights DelveInsight | Novartis, ApoPharma, Indivior Inc., Boehringer Ingelheim, Ocera Therapeutics, Orient Europharma, Karyopharm - Barchart.com

May 28, 2025

May 27, 2025

Focus Partners Wealth Makes New Investment in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - Defense World

May 27, 2025

May 26, 2025

Here's Why Karyopharm Therapeutics (KPTI) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance

May 26, 2025

May 25, 2025

Karyopharm Therapeutics’ SWOT analysis: oncology firm’s stock faces pivotal year - Investing.com Nigeria

May 25, 2025

May 24, 2025

Investors Don't See Light At End Of Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) Tunnel And Push Stock Down 27% - simplywall.st

May 24, 2025

May 22, 2025

Here's Why Shareholders May Want To Be Cautious With Increasing Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) CEO Pay Packet - simplywall.st

May 22, 2025

May 21, 2025

Karyopharm at RBC Capital Markets: Strategic Insights on XPOVIO and Pipeline - Investing.com Australia

May 21, 2025

May 20, 2025

Karyopharm to Participate at the 2025 RBC Capital Markets Global Healthcare Conference - Eastern Progress

May 20, 2025

May 19, 2025

Does Karyopharm Therapeutics (KPTI) Have the Potential to Rally 521.62% as Wall Street Analysts Expect? - sharewise

May 19, 2025

Karyopharm to Participate at the 2025 RBC Capital Markets Global Healthcare Conference | KPTI Stock News - GuruFocus

May 19, 2025

May 16, 2025

StockNews.com Downgrades Karyopharm Therapeutics (NASDAQ:KPTI) to Sell - Defense World

May 16, 2025

Leerink Partnrs Issues Positive Estimate for KPTI Earnings - Defense World

May 16, 2025

Brokerages Set Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Price Target at $45.60 - Defense World

May 16, 2025

Karyopharm targets $1B peak U.S. revenue in myelofibrosis as Phase 3 SENTRY enrollment nears completion - MSN

May 16, 2025

May 15, 2025

Karyopharm’s Earnings Call: Clinical Gains Amid Financial Strains - TipRanks

May 15, 2025

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q1 2025 Earnings Call Transcript - Insider Monkey

May 15, 2025

Robert W. Baird Issues Pessimistic Forecast for Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price - Defense World

May 15, 2025

Karyopharm Announces Poster Presentation on Selinexor in Myelofi - GuruFocus

May 15, 2025

May 14, 2025

KPTI to Present Promising Selinexor Data at Upcoming Hematology Meeting | KPTI Stock News - GuruFocus

May 14, 2025

Karyopharm abstract selected for presentation at 2025 EHA meeting - TipRanks

May 14, 2025

Karyopharm Announces Poster Presentation on Selinexor in Myelofibrosis at the 2025 European Hematology Association Annual Meeting - PR Newswire

May 14, 2025

May 13, 2025

KPTI: RBC Capital Lowers Price Target while Maintaining Outperform Rating | KPTI Stock News - GuruFocus

May 13, 2025

RBC Capital cuts Karyopharm stock price target to $33 By Investing.com - Investing.com Canada

May 13, 2025

KPTI: RBC Capital Lowers Price Target while Maintaining Outperfo - GuruFocus

May 13, 2025

These Analysts Revise Their Forecasts On Karyopharm Therapeutics After Q1 Results - Benzinga

May 13, 2025

RBC Adjusts Price Target on Karyopharm Therapeutics to $33 From $43, Maintains Outperform Rating - marketscreener.com

May 13, 2025

Barclays Updates Karyopharm (KPTI) Price Target, Eyes Future Dat - GuruFocus

May 13, 2025